Study links astrocyte dysfunction to epilepsy in children with tuberous sclerosis

A scientific study by researchers at the University of California, Berkeley has identified a potential disease mechanism behind epileptic seizures associated with tuberous sclerosis, a genetic disorder that can cause severe, drug-resistant seizures. The findings indicate that dysfunction in brain astrocytes may contribute to the development of the disease, rather than being solely a consequence of repeated seizures.

According to the study, published in the journal Nature on September 23, loss of function in the TSC2 gene disrupts the development of neural progenitor cells, leading them to produce enlarged, hyperactive astrocytes associated with heightened inflammatory responses. The results suggest these cells may play a key role in the pathological changes seen in tuberous sclerosis.

The research was led by Dr. Helen Bateup, a scientist at the University of California, Berkeley. Her team used miniature models of human brain tissue known as "brain organoids," which are developed in the lab from human stem cells to mimic certain stages of early brain development.

These three-dimensional models allow researchers to observe brain cell development in a way that more closely resembles the human brain, compared to traditional two-dimensional cell cultures and mouse models, which have failed to replicate the full spectrum of symptoms seen in patients with tuberous sclerosis.

The findings support the hypothesis that astrocytes—a type of glial cell that supports and regulates neurons—may be key drivers of the disease-related changes. This raises the possibility that dysfunction in these cells begins during brain development, rather than arising later as a result of seizures.

The researchers believe that targeting hyperactive astrocytes could open the door to potential therapeutic strategies, especially as experimental drugs exist that may reduce inflammation linked to these cells.

However, this possibility remains under scientific investigation and does not represent a proven treatment for tuberous sclerosis or its associated seizures.

Bateup began studying the disease nearly 20 years ago, initially using mouse models and two-dimensional cell cultures, before turning to brain organoids as the technology advanced, enabling more detailed observation of changes during neural and glial cell development.

The research team also identified similarities between certain molecular changes in astrocytes linked to tuberous sclerosis and those found in neurodegenerative diseases, highlighting the importance of continued study to understand disease mechanisms that may overlap across different neurological disorders.

The study underscores the potential of human brain organoid models to reveal mechanisms of neurological disease and explore possible therapeutic targets, while emphasizing the need for further research to determine how these findings might benefit patients.